A vaccine candidate from AstraZeneca and the University of Oxford is the latest to be shown highly effective against COVID-19. Emergency use authorization will be sought in the United States, the U.K. drugmaker announced Monday.
The drug reduces the risk of contracting the coronavirus by 70% overall, according to the outcome of two different dosing trials. It was 90% effective when participants received an initial half dose and then a full dose a month apart. It was effective 62% of the time when given as two full doses at least one month apart, AstraZeneca reported.
The global trials evaluated participants aged 18 years or over from diverse racial and geographic groups who were healthy or had stable underlying medical conditions. The drug was well-tolerated, with no severe cases of the disease or hospitalization among vaccine recipients, the company said.
The vaccine can be stored and transported at normal refrigerated conditions for at least six months, and administered within existing healthcare settings, it added.
AstraZeneca is the third drug developer to announce positive trial findings for a COVID-19 vaccine during the pandemic. Candidates developed by Pfizer and Moderna have shown more than 90% efficacy. Each company has applied to the FDA for emergency use approval and is now awaiting a Dec. 10 review by the agency’s vaccine advisory panel.